Dermatology Doctors in Oceanside, NY Accepting Medicare
9 Dermatology doctors found. Showing 1 - 9
 Dr. Eve Lowenstein, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-255-0684 |
 Dr. Michael Cohen, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 Fax: 516-255-5353 |
Dr. Barrett Eisenstat, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 |
Dr. Craig Kornreich, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 Fax: 516-255-5353 |
Elie B Lowenstein, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 Fax: 516-634-0196 |
Dr. Russell W Cohen, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 Fax: 516-255-5353 |
Dr. William Lefing, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2940 Lower Lincoln Ave, Oceanside, NY 11572 Phone: 516-678-3966 |
Dr. Roxanne Judith Abitbol, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 Fax: 516-255-5353 |
Dr. Sari Beth Weinstein, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 258 Merrick Rd, Oceanside, NY 11572 Phone: 516-766-0345 |
News Archive
Deep learning tool predicts hosts based on early SARS-CoV-2 samples
The study, which appeared on the pre-print server bioRxiv*, revealed how DeepHoF could help prevent future outbreaks that may become as large as the current pandemic.
FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure
Cumberland Pharmaceuticals Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (acetylcysteine) Injection to treat patients with non-acetaminophen induced acute liver failure.
Cancer risk from HRT remains long after treatment has stopped
The results of a new study have shown that the risk of cancer associated with Hormone Replacement Therapy (HRT) continues long after a woman stops taking it.
Gram-negative bacteria found to be risk factor for worse outcomes in hospitalized ILD patients
Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases. In a study at CHEST 2018, researchers at Beaumont Health Systems studied the influence of bacterial virulence on clinical outcomes patients hospitalized with ILD patients.
OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").
› Verified 5 days ago
Anesthesiology
Internal Medicine
Family Medicine
Emergency Medicine
Pediatrics
Radiology
Dermatology
Hospitalist
Pathology
Obstetrics & Gynecology
Psychiatry & Neurology